Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes

Gina Ryan, Tim A. Briscoe, Lynetta Johnson Jobe

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

Pramlintide (Symlin®), a synthetic analog of a neurohormone amylin, was approved by the US Food and Drug Administration for use along with premeal insulin in patients with type 1. In patients with type 2 diabetes, pramlintide is approved for addition to premeal insulin in those patients who are either only on premeal insulin or those receiving the combination of insulin and metformin and/or a sulfonylurea. This article reviews the pharmacology, pharmacokinetics, dosing, clinical trials, safety, contraindications, and drug interactions of pramlintide therapy. A search for published clinical trials and therapeutic reviews in the English language was done in the following databases: Iowa Drug Information Service (1966 to July 2008), MEDLINE (1966 to July 2008), and International Pharmaceutical Abstracts (1970 to July 2008). Pramlintide and amylin were used as keywords and title words. References of key articles were also reviewed to identify additional publications. Amylin is a 37 amino acid peptide neurohormone cosecreted from the beta cells of the pancreas, along with insulin, in response to meals. Amylin lowers serum glucose by decreasing glucagon release, slowing gastric emptying and decreasing food intake. Pramlintide, a synthetic analog of amylin, reduces 2-hour postprandial blood glucose between 3.4 and 5 mmol/L, reduces A1C by 0.2% to 0.7% and has no effect on fasting glucose levels. The use of pramlintide was associated with up to a 1.6 kg weight loss. Nausea was the most commonly reported adverse event. Pramlintide is an amylin analog that was FDA approved for the treatment of type 1 and type 2 diabetes. Its use results in modest reduction of A1C and the most frequent side effects are hypoglycemia and nausea.

Original languageEnglish (US)
Pages (from-to)203-214
Number of pages12
JournalDrug Design, Development and Therapy
Issue number2
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Islet Amyloid Polypeptide
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Insulin
Therapeutics
Nausea
Neurotransmitter Agents
Drug Information Services
Clinical Trials
Glucose
pramlintide
Metformin
Gastric Emptying
United States Food and Drug Administration
Glucagon
Drug Interactions
Hypoglycemia
MEDLINE
Meals
Blood Glucose

Keywords

  • Amylin
  • Pramlintide
  • Type 1 diabetes
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. / Ryan, Gina; Briscoe, Tim A.; Jobe, Lynetta Johnson.

In: Drug Design, Development and Therapy, No. 2, 01.12.2008, p. 203-214.

Research output: Contribution to journalReview article

Ryan, Gina ; Briscoe, Tim A. ; Jobe, Lynetta Johnson. / Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. In: Drug Design, Development and Therapy. 2008 ; No. 2. pp. 203-214.
@article{44f1fbb2c5764b8bb34c1330c02b75a2,
title = "Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes",
abstract = "Pramlintide (Symlin{\circledR}), a synthetic analog of a neurohormone amylin, was approved by the US Food and Drug Administration for use along with premeal insulin in patients with type 1. In patients with type 2 diabetes, pramlintide is approved for addition to premeal insulin in those patients who are either only on premeal insulin or those receiving the combination of insulin and metformin and/or a sulfonylurea. This article reviews the pharmacology, pharmacokinetics, dosing, clinical trials, safety, contraindications, and drug interactions of pramlintide therapy. A search for published clinical trials and therapeutic reviews in the English language was done in the following databases: Iowa Drug Information Service (1966 to July 2008), MEDLINE (1966 to July 2008), and International Pharmaceutical Abstracts (1970 to July 2008). Pramlintide and amylin were used as keywords and title words. References of key articles were also reviewed to identify additional publications. Amylin is a 37 amino acid peptide neurohormone cosecreted from the beta cells of the pancreas, along with insulin, in response to meals. Amylin lowers serum glucose by decreasing glucagon release, slowing gastric emptying and decreasing food intake. Pramlintide, a synthetic analog of amylin, reduces 2-hour postprandial blood glucose between 3.4 and 5 mmol/L, reduces A1C by 0.2{\%} to 0.7{\%} and has no effect on fasting glucose levels. The use of pramlintide was associated with up to a 1.6 kg weight loss. Nausea was the most commonly reported adverse event. Pramlintide is an amylin analog that was FDA approved for the treatment of type 1 and type 2 diabetes. Its use results in modest reduction of A1C and the most frequent side effects are hypoglycemia and nausea.",
keywords = "Amylin, Pramlintide, Type 1 diabetes, Type 2 diabetes",
author = "Gina Ryan and Briscoe, {Tim A.} and Jobe, {Lynetta Johnson}",
year = "2008",
month = "12",
day = "1",
language = "English (US)",
pages = "203--214",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes

AU - Ryan, Gina

AU - Briscoe, Tim A.

AU - Jobe, Lynetta Johnson

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Pramlintide (Symlin®), a synthetic analog of a neurohormone amylin, was approved by the US Food and Drug Administration for use along with premeal insulin in patients with type 1. In patients with type 2 diabetes, pramlintide is approved for addition to premeal insulin in those patients who are either only on premeal insulin or those receiving the combination of insulin and metformin and/or a sulfonylurea. This article reviews the pharmacology, pharmacokinetics, dosing, clinical trials, safety, contraindications, and drug interactions of pramlintide therapy. A search for published clinical trials and therapeutic reviews in the English language was done in the following databases: Iowa Drug Information Service (1966 to July 2008), MEDLINE (1966 to July 2008), and International Pharmaceutical Abstracts (1970 to July 2008). Pramlintide and amylin were used as keywords and title words. References of key articles were also reviewed to identify additional publications. Amylin is a 37 amino acid peptide neurohormone cosecreted from the beta cells of the pancreas, along with insulin, in response to meals. Amylin lowers serum glucose by decreasing glucagon release, slowing gastric emptying and decreasing food intake. Pramlintide, a synthetic analog of amylin, reduces 2-hour postprandial blood glucose between 3.4 and 5 mmol/L, reduces A1C by 0.2% to 0.7% and has no effect on fasting glucose levels. The use of pramlintide was associated with up to a 1.6 kg weight loss. Nausea was the most commonly reported adverse event. Pramlintide is an amylin analog that was FDA approved for the treatment of type 1 and type 2 diabetes. Its use results in modest reduction of A1C and the most frequent side effects are hypoglycemia and nausea.

AB - Pramlintide (Symlin®), a synthetic analog of a neurohormone amylin, was approved by the US Food and Drug Administration for use along with premeal insulin in patients with type 1. In patients with type 2 diabetes, pramlintide is approved for addition to premeal insulin in those patients who are either only on premeal insulin or those receiving the combination of insulin and metformin and/or a sulfonylurea. This article reviews the pharmacology, pharmacokinetics, dosing, clinical trials, safety, contraindications, and drug interactions of pramlintide therapy. A search for published clinical trials and therapeutic reviews in the English language was done in the following databases: Iowa Drug Information Service (1966 to July 2008), MEDLINE (1966 to July 2008), and International Pharmaceutical Abstracts (1970 to July 2008). Pramlintide and amylin were used as keywords and title words. References of key articles were also reviewed to identify additional publications. Amylin is a 37 amino acid peptide neurohormone cosecreted from the beta cells of the pancreas, along with insulin, in response to meals. Amylin lowers serum glucose by decreasing glucagon release, slowing gastric emptying and decreasing food intake. Pramlintide, a synthetic analog of amylin, reduces 2-hour postprandial blood glucose between 3.4 and 5 mmol/L, reduces A1C by 0.2% to 0.7% and has no effect on fasting glucose levels. The use of pramlintide was associated with up to a 1.6 kg weight loss. Nausea was the most commonly reported adverse event. Pramlintide is an amylin analog that was FDA approved for the treatment of type 1 and type 2 diabetes. Its use results in modest reduction of A1C and the most frequent side effects are hypoglycemia and nausea.

KW - Amylin

KW - Pramlintide

KW - Type 1 diabetes

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=77953677942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953677942&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:77953677942

SP - 203

EP - 214

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

IS - 2

ER -